Cordio Medical develops HearO®, a patient-tailored medical speech processing platform that monitors health conditions via a smartphone app. Its technology uses proprietary true speech signal processing unique to each patient, augmented with machine learning for near real-time monitoring and early detection of condition deterioration. The system continuously learns a patient’s voice to provide personalized, seamless monitoring intended to help physicians prevent deterioration and hospitalization. Cordio raised $18M and plans to deploy the funds to support clinical studies, partnerships, operations, and R&D. Retail and distribution of current and future HearO® versions and clinical operations will be based in Israel and the EU, and the company seeks U.S. market entry in early 2024 pending final FDA approval. Leadership includes CEO Tamir Tal and Chairman Eyal Lifschitz.

Total raised

$18M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2022